Last Updated January 31, 2024

 January 31, 2024

When looking to conduct weight loss study, researchers may be wondering if there are any effective semaglutide natural alternatives.

This detailed review will discuss a few popular over-the-counter (OTC) supplements for weight loss and glycemic control and compare them to semaglutide.

In this comprehensive guide, we’ll answer common questions such as:

  • Is there a natural alternative to semaglutide for weight loss?
  • How do OTC options compare against semaglutide for weight loss?
  • What other peptides are alternatives to semaglutide in weight loss trials?

Keep reading to learn about supplements for weight loss and glycemic control and how they stack up against semaglutide's clinical trial record. We will also share our most trusted source for purchasing high-quality semaglutide online.

Buy Semaglutide from our top-rated vendor...

Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.


What is Semaglutide?

Semaglutide is an anti-diabetic and weight-loss peptide developed by the pharmaceutical company Novo Nordisk. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the function of the naturally-occurring GLP-1 hormone [1].

Semaglutide was initially developed for glycemic control and designed to mimic the glucose-lowering effects of GLP-1 through enhanced pharmacokinetics [1]. Its developers achieved this by modifying the hormone's active form GLP-1 (7-37) at several positions, including the addition of an octadecanoic (C-18) diacid moiety [2, 3].

As a result, semaglutide shares 94% homology with the GLP-1 hormone and has similar affinity to the GLP-1 receptors. It has a half-life of about 7 days, allowing for once-weekly administration subcutaneously [3, 4].

In addition to subcutaneous, semaglutide is the only GLP-1 receptor agonist that is available in oral form. Semaglutide tablets have been approved since 2019 by the United States Food and Drug Administration (FDA) as a treatment of type 2 diabetes (T2D) under the brand name Rybelsus [2, 5].

Injectable semaglutide is also approved for a variety of indications. Here’s a timeline of key regulatory milestones:

2017 

Injectable semaglutide is first approved for human use by the FDA as a once-weekly subcutaneous injection at up to 1.0mg/weekly under the brand name Ozempic [6].

2020

Injectable semaglutide (Ozempic) is approved for reducing the risk of major adverse cardiovascular events (MACE) in T2D patients [7].

2021 

Injectable semaglutide is approved in doses of up to 2.4mg/weekly under the brand name Wegovy as a weight loss therapy in adults with a BMI≥27 (and weight-related comorbidities) or BMI≥30 [6].

2022 

Semaglutide (Ozempic) is authorized for T2D management at a higher dose of 2mg/weekly [8].

2023 

Semaglutide (Wegovy) is approved for adolescents aged 12-17 who classify as obese (with a BMI for age and sex at the 95th percentile) [9].


Semaglutide Natural Alternatives


How Does Semaglutide Work?

Semaglutide works by activating GLP-1 receptors in target organs such as the exocrine pancreas, the brain, the stomach, the intestines, and white adipose tissue [10].

Here is a short guide to the main effects of semaglutide on each organ and the corresponding benefits:

Exocrine pancreas 

Semaglutide interacts with beta cells to stimulate insulin production, which increases uptake of glucose and lowers blood sugar. It also suppresses glucagon production by pancreatic alpha cells, thus reducing gluconeogenesis and glycogenolysis [4].

Stomach

The peptide slows gastric emptying by 38% for a few hours after a meal. This lowers postprandial glucose spikes and may induce early satiety [11].

Small intestine 

GLP-1 agonists like semaglutide stimulate the production of a peptide called Peptide YY (PYY) that acts as a natural appetite-suppressant. PYY is produced by the endocrine cells found in the small intestine to regulate hunger and increase satiety [10].

Adipose tissue

GLP-1 agonists like semaglutide may minimize the reduction of leptin production by fat tissue, which typically occurs during fat loss. Leptin suppresses appetite and high leptin levels are associated with more sustainable weight loss [10].

Brain

GLP-1 agonists like semaglutide interact with neurons found in the hunger center of the brain. Specifically, semaglutide’s activation of proopiomelanocortin/cocaine- and amphetamine-regulated transcript (POMC/CART) neurons is believed to promote feelings of fullness [10, 12].

By diminishing hunger and enhancing feelings of fullness, semaglutide can catalyze considerable weight reduction. For instance, a study in 72 obese subjects demonstrated that 20 weeks on semaglutide 2.4mg/weekly caused a 35% decrease in caloric consumption during a free, unrestricted test meal when compared to placebo [13].


Semaglutide for Weight Loss

Semaglutide is approved as a weight loss medication thanks to impressive results from phase-3 trials in the STEP clinical development program [14].

STEP stands for “Semaglutide Treatment Effect in People with Obesity” and is an ongoing program initiated by Novo Nordisk that consists of several studies (STEP 1-10, STEP TEENS, STEP UP, etc.) investigating the effect of semaglutide 2.4mg/weekly on chronic weight management [14].

Here’s a quick guide to some of the most notable published and ongoing trials in the STEP series:

  • STEP-1 is the first and largest STEP trial, involving 1961 nondiabetic but obese or overweight individuals. The authors reported that semaglutide at 2.4mg/weekly led to an average weight loss of 14.9% compared to 2.4% for placebo over 68 weeks. A substudy of this trial employed DEXA scans on 140 of the participants and reported that the weight loss was primarily due to fat loss rather than lean mass reduction [15, 16].
  • STEP-4 included a total of 902 participants at 2.4mg/weekly for an initial period of 20 weeks. The volunteers were then randomly divided to continue the semaglutide regimen or switch to placebo for the remaining 48 weeks. After a total of 68 weeks, the semaglutide group experienced an overall average weight reduction of 17.4%. On the contrary, those transferred to the placebo group regained 6.9% of their body weight for a net mean weight loss of 5.0% [17].
  • STEP-5 is the longest of the STEP trials and spanned 104 weeks at 2.4mg/weekly and reported a favorable safety profile with no serious safety concerns. Weight loss occurred progressively during the first 60 weeks, and was maintained for the rest of the trial. The mean placebo-adjusted weight loss was 12.6% [18].
  • STEP UP and STEP UP T2D are ongoing trials that aim to evaluate the weight loss potential of semaglutide at a yet-to-be-approved dosage of 7.2mg/weekly, comparing it to the established 2.4mg/weekly dose for weight loss [19, 20].

Semaglutide Natural Alternatives | Supplements, Diet, and More

Researchers may be wondering if there are natural supplements or OTC options that could match some of the aforementioned semaglutide benefits.

Below, we discuss some of the most potent over-the-counter supplements for glycemic control and weight loss. All in all, they hold some potential as natural alternatives to semaglutide.

Berberine

Berberine is an alkaloid found in plants like barberries and grapes. Berberine appears to workly mainly by stimulating an enzyme called adenosine monophosphate-activated protein kinase (AMPK) [21].

Activation of this enzyme signals to cells that energy reserves are low, forcing them to draw in glucose from the bloodstream, which lowers blood sugar levels. Several meta-analyses, the largest of which included 46 trials, confirm that berberine supplementation effectively reduces fasting blood sugar levels and improves glycemic control as measured via glycated hemoglobin levels in T2D patients [22, 23].
Researchers also report a potential weight loss effect of berberine, leading to a small reduction in BMI [23]. However, the research supporting its weight loss effects is scarce. Moreover, some authors warn that berberine supplementation may have diminishing returns after several months of use [24].

Chromium

Chromium is an essential mineral found in trace amounts inside a variety of plant products, but especially grains. Its main mechanism is directly tied to chromodulin, a chromium-dependent protein that augments the signaling of insulin receptors. Studies show a reduction in glycated hemoglobin following several weeks of chromium supplementation. However, the research is mixed regarding chromium’s potential to lower fasting blood sugar levels [25, 26].

Therefore, chromium's effects may lie primarily in reducing postprandial blood glucose. Two meta-analyses also suggest chromium may induce a small reduction in body weight (1-2lb) after 12 weeks of supplementation. While chromium is thought to reduce cravings, the evidence on this mineral supplement is still limited [27, 28].

5-HTP

5-HTP (5-Hydroxytryptophan) is a precursor to the neurotransmitter serotonin, and it occurs naturally in many plants, notably including the African plant Griffonia simplicifolia. 5-HTP supplementation appears to help improve mood, but it may also work for weight loss. Researchers have observed an increase in satiety and a decrease in binge eating with supplementation [29].

It may be most effective in individuals prone to emotional or binge eating. Studies in overweight subjects with T2D report significantly reduced appetite and energy intake, ultimately leading to weight loss [30].

While berberine, chromium, and 5-HTP may be among the most effective weight loss and glucose-lowering components in OTC supplements, their effects are clearly limited compared to semaglutide.


Do note…

Moreover, natural options are not necessarily free of side effects or food-drug interactions. For example, berberine can cause gastrointestinal problems such as bloating and constipation. Due to its effect on AMPK, some studies suggest it may also hamper muscle hypertrophy, which is an undesired effect in subjects trying to build muscle [31].

Likewise, 5-HTP containing supplements should not be used alongside antidepressants due to an increased risk of serotonin syndrome [32].

Although semaglutide is not available OTC, qualified researchers can procure it without a prescription from a trusted vendor like our top-rated source for  research purposes.


Optimizing Diet and Lifestyle

Regardless of whether semaglutide or OTC supplements are used, a weight loss intervention should always include lifestyle changes like implementing a healthy diet and exercise regime.

In fact, semaglutide is recommended for use only in conjunction with a balanced diet and exercise to maximize weight loss and ensure sustainable health benefits [6, 13].

Here are 7 evidence-based tips for researchers looking to design a weight loss intervention:

  • Subjects should prioritize low-calorie foods, since maintaining a calorie deficit is essential to successful weight loss interventions. These include foods with low energy density and a low glycemic index, such as non-starchy vegetables, fresh fruits, whole grains, and low fat protein sources [33, 34, 35, 36, 37].
  • Sufficient protein should be consumed at every meal to help stabilize blood sugar levels, prevent muscle wasting during weight loss, increase satiety, and boost energy expenditure. Low calorie protein sources include lean meat, seafood, legumes, and low fat dairy [38].
  • Fiber consumption at every meal increases satiety while helping stabilize blood sugar levels. The best high fiber foods to include are fresh fruits, non-starchy vegetables, and whole grains. Studies also suggest that consuming fiber first during a meal increases satiety for further weight loss benefits [39, 40].
  • Study participants are encouraged to ingest modest meal sizes, maintain consistent meal times, and practice mindful eating. Clinical data indicates a 10% uptick in food intake when meals are consumed amid distractions like electronic devices [41, 42].
  • Study participants must ensure they stay well-hydrated throughout the study. Water needs must be adjusted according to physical exertion, surrounding temperature, and body mass. Drinking water prior to meals has been linked to lower subsequent energy consumption [43].
  • Physical activity is a key element of any weight reduction program. Regular exercise increases caloric expenditure, benefits cardiovascular health, prevents muscle loss during low calorie dieting, and accelerates metabolism [44]. Participants are advised to include aerobic workouts, strength exercises, or a blend of both.
  • Quality sleep is fundamental for weight loss, given its role in managing hormones linked to appetite control and metabolism. Study participants are recommended to strive for a minimum of 7-8 hours of undisturbed sleep per night [45].

Semaglutide Alternatives | Top 3 Peptides

Several other peptides have also been studied for their anti-diabetic and weight-loss properties.

Like semaglutide, some of these such as the dual GIP/GLP-1 agonist tirzepatide and the GLP-1 agonist liraglutide are FDA-approved for certain uses [9].

Here are the top three peptide-based alternatives to semaglutide for weight loss:

  • Tirzepatide works by simultaneously activating the GLP-1 receptors and the receptors for another incretin hormone called GIP (glucose-dependent insulinotropic polypeptide). It has shown superior anti-diabetic and weight-loss properties compared to other incretin mimetics, semaglutide included [46].

    Tirzepatide is already approved for glycemic control in T2D, showing clinically significant reductions in HbA1c from baseline [47, 48]. It is also under active research as a weight loss peptide in phase-3 studies, where it has led to over 20% weight loss within 72 weeks at the full dose of 15mg/weekly [49].

  • Liraglutide is another GLP-1 agonist approved for various indications, including T2D management and weight loss [9]. Studies report that it can cause up to a 2.2% reduction in HbA1c from baseline in T2D subjects [50].

    Liraglutide at its maximum dose of 3.0mg/daily has been reported to cause up to 6.4% weight loss in 68 weeks of administration. Yet, this result is lower compared to the 15.8% drop in body weight at semaglutide 2.4mg/weekly [51].

  • AOD-9604, also known as LAT 8881 or Tyr-hGH 177-191, is a modified C-terminal fragment of the human growth hormone. It is known as HGH’s lipolytic fragment that stimulates fat loss without counteracting the effects of insulin, stimulating IGF-1 synthesis, or inducing cell proliferation [52].

    Rat studies suggest that this HGH fragment may lead to a 50% weight reduction in obese animals without increasing the risk of insulin resistance [53]. Clinical research reports that the peptide may lead to a significant weight reduction in obese subjects within 12 weeks of administration. However, clinical findings to date on AOD-9604 are inconsistent, with some trials reporting no effect on weight loss [54].


Is Semaglutide Safe?

Semaglutide is FDA-approved for multiple indications and is considered safe for use in both diabetics and non-diabetics [6, 55].

But like other peptides in its class, semaglutide is not free of side effects. Similar to other GLP-1 receptor agonists, semaglutide is associated with gastrointestinal (GI) complaints [4, 6].

For example, the largest STEP trial published to date reported that GI issues affected 74.2% of volunteers taking semaglutide, as opposed to 47.9% taking placebo. The most common GI side effects reported were [15]:

  • Nausea (44.2%)
  • Diarrhea (31.5%)
  • Vomiting (24.8%)
  • Constipation (23.4%)
  • Dyspepsia (10.3%)
  • Abdominal pain (10.0%)

The trial also reported potentially serious side effects that may occur due to the inhibitory effect of GLP-1 on cholecystokinin synthesis and gallbladder motility, which delays gallbladder emptying [56].

According to the STEP-1 trial, these events were of mild to moderate intensity and resolved without complications. Overall, they affected less than 3% of study volunteers and included [15]:

  • Hepatic disorders
  • Cholelithiasis
  • Acute pancreatitis

Local site reactions following subcutaneous semaglutide may also include redness, swelling, inflammation, bleeding, and pain. These were reported with 5-7% incidence in both the semaglutide and placebo groups.

Researchers should also consider the contraindications for semaglutide, including:

  • History of thyroid cancer
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Pregnancy
  • Lactation
  • Known allergy to semaglutide

Animal studies suggest that GLP-1-RAs, including semaglutide, could lead to reduced embryo size and developmental anomalies. Based on these concerns, pregnant women should be excluded from semaglutide trials [57].

Data from rat studies has likewise demonstrated an increased risk of thyroid C-cell carcinoma at high semaglutide doses. This is why a history of thyroid cancer or MEN 2 (multiple endocrine neoplasia type 2) is contraindicated for semaglutide use. The thyroid C-cell carcinoma risk observed in animal studies has yet to be confirmed in human trials [58].


Semaglutide Natural Alternatives


Where to Buy Semaglutide Online? | 2024 Edition

Researchers and laboratory specialists in need of semaglutide for scientific investigation are well-advised to carefully choose where to source it online.

We recommend the two following top retailers.

Limitless Life

After reviewing multiple online peptide stores, we recommend Limitless Life as a reliable supplier of research-grade semaglutide, available through their VIP Club.

Here is why we trust this vendor:

  • Superior Purity: All peptides from Limitless Life undergo rigorous HPLC-MS testing at an independent laboratory. This meticulous process ensures product purity of 99%.
  • Payment Methods: Limitless Life accommodates a wide range of payment methods, including credit cards, cryptocurrencies, and CashApp.
  • Service and Support: Limitless Life’s proficient service and support team is available by phone and email to address all queries and concerns.
  • Reliable Shipping: Limitless Life provides swift, reliable, and budget-friendly shipping solutions, with the fee waived for domestic orders of $350+.

Click the link below to sign up for the Limitless VIP Club to gain special access to semaglutide and other innovative research chemicals. Sign up is simple and instant:

Buy Semaglutide from our top-rated vendor...


Research Chemical

Research Chemical also earns our endorsement as a top online supplier of research-grade semaglutide.

Here’s why they are worthy of consideration:

  • Pure Peptides: Research Chemical sources their semaglutide exclusively from accredited American facilities and subjects each batch to rigorous quality testing.
  • Easy Checkout: Research Chemical’s website provides a secure shopping experience with a range of payment options on offer, including credit cards, e-checks, and cryptocurrencies.
  • Outstanding Support and Service: The vendor’s amiable customer service staff is always on hand to answer any questions about the company’s products.

Get 15% off at Research Chemical by entering the promo code “peptides15” at checkout.

Buy research peptides from Research Chemical today...


Natural Alternatives to Semaglutide | Verdict

Semaglutide is a GLP-1 receptor agonist that is FDA-approved for a variety of indications, including glycemic control in T2D and chronic weight management in adolescents and adults.

OTC supplements like berberine, chromium, and 5-HTP may be used as natural alternatives to semaglutide.

However, the weight loss and glucose-lowering potential of these dietary supplements is much lower compared to pharmacological compounds like semaglutide, liraglutide, and tirzepatide.

Scientists who wish to obtain high-quality semaglutide online should buy it strictly from a vetted vendor like our top-rated one here.


References

  1. Rehfeld JF. The Origin and Understanding of the Incretin Concept. Front Endocrinol (Lausanne). 2018 Jul 16;9:387. doi: 10.3389/fendo.2018.00387. PMID: 30061863; PMCID: PMC6054964.
  2. Kalra S, Sahay R. A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. Diabetes Ther. 2020 Sep;11(9):1965-1982. doi: 10.1007/s13300-020-00894-y. Epub 2020 Jul 28. PMID: 32725484; PMCID: PMC7434819.
  3. Al Musaimi O, Al Shaer D, de la Torre BG, Albericio F. 2017 FDA Peptide Harvest. Pharmaceuticals (Basel). 2018 May 7;11(2):42. doi: 10.3390/ph11020042. PMID: 29735913; PMCID: PMC6027222.
  4. Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7. PMID: 34993760; PMCID: PMC8736331.
  5. Hughes S, Neumiller JJ. Oral Semaglutide. Clin Diabetes. 2020 Jan;38(1):109-111. doi: 10.2337/cd19-0079. PMID: 31975761; PMCID: PMC6969659.
  6. Chao AM, Tronieri JS, Amaro A, Wadden TA. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Drug Des Devel Ther. 2022 Dec 29;16:4449-4461. doi: 10.2147/DDDT.S365416. PMID: 36601368; PMCID: PMC9807016.
  7. Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022 Oct;23(5):979-994. doi: 10.1007/s11154-022-09735-8. Epub 2022 Jul 15. PMID: 35838946; PMCID: PMC9515042.
  8. Highlights of prescribing information … – novo nordisk. (n.d.). Retrieved July 26, 2023, from https://www.novo-pi.com/ozempic.pdf
  9. Berman C, Vidmar AP, Chao LC. Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth. touchREV Endocrinol. 2023 May;19(1):38-45. doi: 10.17925/EE.2023.19.1.38. Epub 2023 May 23. PMID: 37313232; PMCID: PMC10258616.
  10. Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021 Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0. Epub 2021 May 11. PMID: 33977495; PMCID: PMC8189979.
  11. Jensterle, M., Ferjan, S., Ležaič, L., Sočan, A., Goričar, K., Zaletel, K., & Janez, A. (2023). Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, obesity & metabolism, 25(4), 975–984. https://doi.org/10.1111/dom.14944
  12. van Bloemendaal, L., IJzerman, R. G., Ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014). GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes, 63(12), 4186–4196. https://doi.org/10.2337/db14-0849
  13. Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, obesity & metabolism, 23(3), 754–762. https://doi.org/10.1111/dom.14280
  14. Alabduljabbar, K., Al-Najim, W., & le Roux, C. W. (2022). The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. Nutrients, 14(11), 2217. https://doi.org/10.3390/nu14112217
  15. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
  16. O'Neil PM, Rubino DM. Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. Postgrad Med. 2022 Jan;134(sup1):28-36. doi: 10.1080/00325481.2022.2150006. PMID: 36691307.
  17. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. PMID: 33755728; PMCID: PMC7988425.
  18. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., … & STEP 5 Study Group. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine, 28(10), 2083-2091.
  19. National Library of Medicine (U.S.). (2023, Jan 4 – ). A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) (STEP UP). Identifier NCT05646706. https://clinicaltrials.gov/ct2/show/NCT05646706
  20. National Library of Medicine (U.S.). (2023, Jan 4 – ). A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight. Identifier NCT05649137. https://clinicaltrials.gov/ct2/show/NCT05649137
  21. Ilyas, Z., Perna, S., Al-Thawadi, S., Alalwan, T. A., Riva, A., Petrangolini, G., Gasparri, C., Infantino, V., Peroni, G., & Rondanelli, M. (2020). The effect of berberine on weight loss in order to prevent obesity: A systematic review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 127, 110137. https://doi.org/10.1016/j.biopha.2020.110137
  22. Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., Xu, N., Hou, K., Hu, Z., Chen, Y., & Chen, R. (2022). Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Frontiers in pharmacology, 13, 1015045. https://doi.org/10.3389/fphar.2022.1015045
  23. Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y., & Liu, W. J. (2021). The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxidative medicine and cellular longevity, 2021, 2074610. https://doi.org/10.1155/2021/2074610
  24. Liang, Y., Xu, X., Yin, M., Zhang, Y., Huang, L., Chen, R., & Ni, J. (2019). Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocrine journal, 66(1), 51–63. https://doi.org/10.1507/endocrj.EJ18-0109
  25. Zhao, F., Pan, D., Wang, N., Xia, H., Zhang, H., Wang, S., & Sun, G. (2022). Effect of Chromium Supplementation on Blood Glucose and Lipid Levels in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis. Biological trace element research, 200(2), 516–525. https://doi.org/10.1007/s12011-021-02693-3
  26. Asbaghi, O., Fatemeh, N., Mahnaz, R. K., Ehsan, G., Elham, E., Behzad, N., Damoon, A. L., & Amirmansour, A. N. (2020). Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacological research, 161, 105098. https://doi.org/10.1016/j.phrs.2020.105098
  27. Tian, H., Guo, X., Wang, X., He, Z., Sun, R., Ge, S., & Zhang, Z. (2013). Chromium picolinate supplementation for overweight or obese adults. The Cochrane database of systematic reviews, 2013(11), CD010063. https://doi.org/10.1002/14651858.CD010063.pub2
  28. Tsang, C., Taghizadeh, M., Aghabagheri, E., Asemi, Z., & Jafarnejad, S. (2019). A meta-analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity. Clinical obesity, 9(4), e12313. https://doi.org/10.1111/cob.12313
  29. Cangiano, C., Ceci, F., Cascino, A., Del Ben, M., Laviano, A., Muscaritoli, M., Antonucci, F., & Rossi-Fanelli, F. (1992). Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. The American journal of clinical nutrition, 56(5), 863–867. https://doi.org/10.1093/ajcn/56.5.863
  30. Cangiano, C., Laviano, A., Del Ben, M., Preziosa, I., Angelico, F., Cascino, A., & Rossi-Fanelli, F. (1998). Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 22(7), 648–654. https://doi.org/10.1038/sj.ijo.0800642
  31. Wang, H., Liu, D., Cao, P., Lecker, S., & Hu, Z. (2010). Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine. Diabetes, 59(8), 1879–1889. https://doi.org/10.2337/db10-0207
  32. Patel, Y. A., & Marzella, N. (2017). Dietary Supplement-Drug Interaction-Induced Serotonin Syndrome Progressing to Acute Compartment Syndrome. The American journal of case reports, 18, 926–930. https://doi.org/10.12659/ajcr.904375
  33. Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., Leboff, M. S., Rood, J. C., de Jonge, L., Greenway, F. L., Loria, C. M., Obarzanek, E., & Williamson, D. A. (2009). Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. The New England journal of medicine, 360(9), 859–873. https://doi.org/10.1056/NEJMoa0804748
  34. Naude, C. E., Schoonees, A., Senekal, M., Young, T., Garner, P., & Volmink, J. (2014). Low carbohydrate versus isoenergetic balanced diets for reducing weight and cardiovascular risk: a systematic review and meta-analysis. PloS one, 9(7), e100652. https://doi.org/10.1371/journal.pone.0100652
  35. Westerterp K. R. (2010). Physical activity, food intake, and body weight regulation: insights from doubly labeled water studies. Nutrition reviews, 68(3), 148–154. https://doi.org/10.1111/j.1753-4887.2010.00270.x
  36. Hill, J. O., Wyatt, H. R., & Peters, J. C. (2012). Energy balance and obesity. Circulation, 126(1), 126–132. https://doi.org/10.1161/CIRCULATIONAHA.111.087213
  37. Strasser, B., Spreitzer, A., & Haber, P. (2007). Fat loss depends on energy deficit only, independently of the method for weight loss. Annals of nutrition & metabolism, 51(5), 428–432. https://doi.org/10.1159/000111162
  38. Moon, J., & Koh, G. (2020). Clinical Evidence and Mechanisms of High-Protein Diet-Induced Weight Loss. Journal of obesity & metabolic syndrome, 29(3), 166–173. https://doi.org/10.7570/jomes20028
  39. Howarth, N. C., Saltzman, E., & Roberts, S. B. (2001). Dietary fiber and weight regulation. Nutrition reviews, 59(5), 129–139. https://doi.org/10.1111/j.1753-4887.2001.tb07001.x
  40. Kubota, S., Liu, Y., Iizuka, K., Kuwata, H., Seino, Y., & Yabe, D. (2020). A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes. Nutrients, 12(9), 2502. https://doi.org/10.3390/nu12092502
  41. Robinson, E., Aveyard, P., Daley, A., Jolly, K., Lewis, A., Lycett, D., & Higgs, S. (2013). Eating attentively: a systematic review and meta-analysis of the effect of food intake memory and awareness on eating. The American journal of clinical nutrition, 97(4), 728–742. https://doi.org/10.3945/ajcn.112.045245
  42. Davis, R., Rogers, M., Coates, A. M., Leung, G. K. W., & Bonham, M. P. (2022). The Impact of Meal Timing on Risk of Weight Gain and Development of Obesity: a Review of the Current Evidence and Opportunities for Dietary Intervention. Current diabetes reports, 22(4), 147–155. https://doi.org/10.1007/s11892-022-01457-0
  43. Davy, B. M., Dennis, E. A., Dengo, A. L., Wilson, K. L., & Davy, K. P. (2008). Water consumption reduces energy intake at a breakfast meal in obese older adults. Journal of the American Dietetic Association, 108(7), 1236–1239. https://doi.org/10.1016/j.jada.2008.04.013
  44. Sardeli, A. V., Komatsu, T. R., Mori, M. A., Gáspari, A. F., & Chacon-Mikahil, M. P. T. (2018). Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients, 10(4), 423. https://doi.org/10.3390/nu10040423
  45. Taheri, S., Lin, L., Austin, D., Young, T., & Mignot, E. (2004). Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS medicine, 1(3), e62. https://doi.org/10.1371/journal.pmed.0010062
  46. Vadher, K., Patel, H., Mody, R., Levine, J. A., Hoog, M., Cheng, A. Y., … & Sapin, H. (2022). Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes, Obesity and Metabolism, 24(9), 1861-1868.
  47. Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022). Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. The lancet. Diabetes & endocrinology, 10(9), 623–633. https://doi.org/10.1016/S2213-8587(22)00188-7
  48. Farzam K, Patel P. Tirzepatide. [Updated 2023 May 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585056/
  49. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
  50. Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016). Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes therapy : research, treatment and education of diabetes and related disorders, 7(3), 411–438. https://doi.org/10.1007/s13300-016-0180-0
  51. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., & STEP 8 Investigators (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619
  52. Heffernan, M. A., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., & Ng, F. M. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 25(10), 1442–1449. https://doi.org/10.1038/sj.ijo.0801740
  53. Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone research, 53(6), 274–278. https://doi.org/10.1159/000053183
  54. Valentino, M. A., Lin, J. E., & Waldman, S. A. (2010). Central and peripheral molecular targets for antiobesity pharmacotherapy. Clinical pharmacology and therapeutics, 87(6), 652–662. https://doi.org/10.1038/clpt.2010.57
  55. Highlights of prescribing information … – novo nordisk. (n.d.). Retrieved July 26, 2023, from https://www.novo-pi.com/wegovy.pdf
  56. He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA internal medicine, 182(5), 513–519. https://doi.org/10.1001/jamainternmed.2022.0338
  57. Hefetz, L., Ben-Haroush Schyr, R., Bergel, M., Arad, Y., Kleiman, D., Israeli, H., Samuel, I., Azulai, S., Haran, A., Levy, Y., Sender, D., Rottenstreich, A., & Ben-Zvi, D. (2022). Maternal antagonism of Glp1 reverses the adverse outcomes of sleeve gastrectomy on mouse offspring. JCI insight, 7(7), e156424. https://doi.org/10.1172/jci.insight.156424
  58. Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in endocrinology, 12, 645563. https://doi.org/10.3389/fendo.2021.645563

Scientifically Fact Checked by:

Luis Daniel López Murillo, PhD

Table of Contents
    Add a header to begin generating the table of contents